Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial

Sivagurunathan Sutharsan, Sivagurunathan Sutharsan, Edward F McKone, Damian G Downey, Jamie Duckers, Gordon MacGregor, Elizabeth Tullis, Eva Van Braeckel, Claire E Wainwright, Danie Watson, Neil Ahluwalia, Bote G Bruinsma, Christopher Harris, Anna P Lam, Yiyue Lou, Samuel M Moskowitz, Simon Tian, Jason Yuan, David Waltz, Marcus A Mall, Paul Aurora, Stijn Verhulst, Danie Watson, Michael Lorenz, Jobst Roehmel, Wolfgang Gleiber, Susanne Naehrig, Florian Stehling, Sivagurunathan Sutharsan, Sivagurunathan Sutharsan, Silke van Koningsbruggen-Rietschel, Rainald Fischer, Damian Downey, Charles Haworth, Jamie Duckers, Julian Legg, Peter Barry, Rebecca Thursfield, Simon James Doe, Tom Hilliard, Gordon MacGregor, Edward F Nash, Nicholas John Withers, Daniel Peckham, Helen Louise Barr, Timothy Lee, Robert Gray, Francois Vermeulen, Eva Van Braeckel, Eef Vanderhelst, Philip J Robinson, Claire E Wainwright, Daniel J Smith, Siobhain A Mulrennan, Barry S Clements, Peter Wark